Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways.

IF 3.9 Nanomedicine (London, England) Pub Date : 2025-03-01 Epub Date: 2025-02-09 DOI:10.1080/17435889.2025.2462521

Zahra Esmaeili, Parisa Shavali Gilani, Masood Khosravani, Maral Motamedi, Shokofeh Maleknejad, Mahdi Adabi, Parisa Sadighara

{"title":"Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways.","authors":"Zahra Esmaeili, Parisa Shavali Gilani, Masood Khosravani, Maral Motamedi, Shokofeh Maleknejad, Mahdi Adabi, Parisa Sadighara","doi":"10.1080/17435889.2025.2462521","DOIUrl":null,"url":null,"abstract":"<p><p>Epigallocatechin-3-gallate (EGCG), the primary polyphenol in green tea, is renowned for its potent antioxidant properties. EGCG interacts with various cellular targets, inhibiting cancer cell proliferation through apoptosis and cell cycle arrest induction, while also modulating metabolic pathways. Studies have demonstrated its potential in addressing cancer development, obesity, and diabetes. Given the rising prevalence of metabolic diseases and cancers, EGCG is increasingly recognized as a promising therapeutic agent. This review provides a comprehensive overview of the latest findings on the effects of both free and nano-encapsulated EGCG on mechanisms involved in the management and prevention of hyperlipidemia, diabetes, and gastrointestinal (GI) cancers. The review highlights EGCG role in modulating key signaling pathways, enhancing bioavailability through nano-formulations, and its potential applications in clinical settings.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"621-636"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2462521","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Epigallocatechin-3-gallate (EGCG), the primary polyphenol in green tea, is renowned for its potent antioxidant properties. EGCG interacts with various cellular targets, inhibiting cancer cell proliferation through apoptosis and cell cycle arrest induction, while also modulating metabolic pathways. Studies have demonstrated its potential in addressing cancer development, obesity, and diabetes. Given the rising prevalence of metabolic diseases and cancers, EGCG is increasingly recognized as a promising therapeutic agent. This review provides a comprehensive overview of the latest findings on the effects of both free and nano-encapsulated EGCG on mechanisms involved in the management and prevention of hyperlipidemia, diabetes, and gastrointestinal (GI) cancers. The review highlights EGCG role in modulating key signaling pathways, enhancing bioavailability through nano-formulations, and its potential applications in clinical settings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米技术驱动的EGCG：在代谢和癌症途径中架起抗氧化和治疗作用的桥梁。

表没食子儿茶素-3-没食子酸酯（EGCG）是绿茶中的主要多酚，以其有效的抗氧化特性而闻名。EGCG与多种细胞靶点相互作用，通过诱导细胞凋亡和细胞周期阻滞抑制癌细胞增殖，同时调节代谢途径。研究已经证明了它在治疗癌症发展、肥胖和糖尿病方面的潜力。鉴于代谢性疾病和癌症的患病率不断上升，EGCG越来越被认为是一种有前途的治疗药物。本文综述了游离EGCG和纳米封装EGCG在高脂血症、糖尿病和胃肠道（GI）癌症的管理和预防机制中的作用的最新发现。这篇综述强调了EGCG在调节关键信号通路中的作用，通过纳米配方提高生物利用度，以及它在临床环境中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量